Atlas Venture Fund X, L.P.'s Net Worth

$533 Million

Estimate Recalculated Feb 27, 2024 05:40PM EST

Who is Atlas Venture Fund X, L.P.?

Atlas Venture Fund X, L.P. has an estimated net worth of $533 Million. This is based on reported shares across multiple companies, which include Generation Bio Co., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., and AVROBIO, Inc..

SEC CIK

Atlas Venture Fund X, L.P.'s CIK is 0001628098

Past Insider Trading and Trends

2018 was Atlas Venture Fund X, L.P.'s most active year for acquiring shares with 6 total transactions. Atlas Venture Fund X, L.P.'s most active month to acquire stocks was the month of May. 2023 was Atlas Venture Fund X, L.P.'s most active year for disposing of shares, totalling 34 transactions. Atlas Venture Fund X, L.P.'s most active month to dispose stocks was the month of November. 2019 saw Atlas Venture Fund X, L.P. paying a total of $15,000,003.50 for 825,056 shares, this is the most they've acquired in one year. In 2023 Atlas Venture Fund X, L.P. cashed out on 1,033,086 shares for a total of $53,343,252.37, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Generation Bio Co. (GBIO) Snapshot price: $1.875

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-11.73%
-1.10M
8.28M
Scheduled
Sep 17
Form 4
-10.50%
-1.10M
9.38M
Scheduled
Jun 16
Form 4
-9.89%
-1.00M
9.11M
Scheduled
Mar 16
Form 4
-9.12%
-1.15M
11.48M
Scheduled
Dec 15
Form 4
+387.54%
10.04M
12.63M
Jun 16
Form 3
0
0
No matching records found

Replimune Group, Inc. (REPL) Snapshot price: $7.425

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-15.19%
-445.34K
2.49M
Scheduled
Sep 15
Form 4
-13.19%
-445.34K
2.93M
Scheduled
Jul 2
Form 4
-11.65%
-445.34K
3.38M
Scheduled
Jun 16
Form 4
-14.17%
-631.07K
3.82M
Scheduled
Feb 12
Form 4
4.45M
4.45M
Jul 24
Form 3
0
0
No matching records found

Ikena Oncology, Inc. (IKNA) Snapshot price: $1.39

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+2,809.29%
4.75M
4.92M
Mar 30
Form 3
0
0
No matching records found

Kymera Therapeutics, Inc. (KYMR) Snapshot price: $34.0875

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-2.11%
-126.47K
$30.22
-$3,821,738.64
5.86M
Scheduled
Jan 11 - Jan 12
Form 4
-6.00%
-382.24K
$31.36
-$11,985,953.69
5.98M
Scheduled
Dec 14 - Dec 15
Form 4
-3.34%
-220.02K
$30.01
-$6,602,952.38
6.37M
Scheduled
Nov 2 - Nov 3
Form 4
-4.20%
-288.70K
$30.26
-$8,735,143.37
6.59M
Scheduled
Oct 28 - Nov 1
Form 4
-16.30%
-1.12M
5.76M
Scheduled
May 18
Form 4
-13.38%
-1.06M
6.89M
Scheduled
Feb 18
Form 4
+1,104.37%
8.31M
9.06M
Aug 25
Form 3
0
0
No matching records found

Magenta Therapeutics, Inc. (DNTH) Snapshot price: $23.55

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-23.53%
-968.73K
3.15M
Scheduled
Feb 11
Form 4
-15.00%
-726.50K
$17.86
-$254,415.70
4.12M
Mar 20
Form 4
+4,906.38%
4.75M
4.84M
Jun 25
Form 3
0
0
No matching records found